Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients
Aim: Kukoamine B, a small molecule compound, is being developed for the treatment of sepsis in a Phase II clinical trial. The objective of this study was to optimize dosing selection for a Phase IIb clinical trial using an exposure-response model.Methods: Data of 34 sepsis patients from a Phase IIa...
Main Authors: | Huanhuan Wang, Xiaoyun Hu, Teng Wang, Cheng Cui, Ji Jiang, Kai Dong, Shuai Chen, Chunyan Jin, Qian Zhao, Bin Du, Pei Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.645130/full |
Similar Items
-
Application Prospect of the SOFA Score and Related Modification Research Progress in Sepsis
by: Xuesong Wang, et al.
Published: (2023-05-01) -
Development and validation of a predictive model for new-onset atrial fibrillation in sepsis based on clinical risk factors
by: Zhuanyun Li, et al.
Published: (2022-08-01) -
Prevalence and outcome of sepsis in respiratory intensive care unit
by: Ashraf M. Madkour, et al.
Published: (2022-05-01) -
Increase Mortality Rate in Sepsis Patients with qSOFA Score Greater than Two
by: Raja Muhammad Waqar Khan, et al.
Published: (2022-12-01) -
The impact of the Sepsis-3 definition on ICU admission of patients with infection
by: Jenny Klimpel, et al.
Published: (2019-11-01)